This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

ONLINE REGISTRATION CLOSES IN:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego
Register Now
Menu
Book
Key Sessions
Aviv Regev, PhD
Cell Atlases as Roadmaps in Health and Disease
Genentech Research and Early Development
Kristian Andersen, PhD
Untangling Pandemics in a Data-driven World
Scripps Research
James Wells, Ph.D.
Discovering and Targeting Neo-epitopes in Cancer
UCSF
Charlotte Deane, PhD
Applications of Machine Learning and Informatics in Antibody and Protein Research
University of Oxford
keyboard_arrow_right

MAIN CONFERENCE DEC.13 - PST/PDT (Pacific Daylight, GMT-7)

keyboard_arrow_leftSearch & Filter
search

MAIN CONFERENCE DEC.13 - PST/PDT (Pacific Daylight, GMT-7)

search
7:00am - 8:00am60 mins
Registration and Coffee
    8:00am - 8:05am5 mins
    Keynote Presentations
    Welcome and Opening Remarks
    • Paul Parren, PhD - EVP, Head of R&D and Professor, Lava Therapeutics and Leiden University
    8:05am - 8:50am45 mins
    Keynote Presentations
    Cell Atlases as Roadmaps in Health and Disease
    • Aviv Regev, PhD - Executive Vice President, Genentech Research and Early Development
    8:50am - 9:35am45 mins
    Keynote Presentations
    Untangling Pandemics in a Data-driven World
    • Kristian Andersen, PhD - Professor, Department of Immunology and Microbiology, Scripps Research
    9:35am - 10:05am30 mins
    Keynote Presentations
    Networking Refreshment Break
      10:05am - 10:50am45 mins
      Keynote Presentations
      Discovering and Targeting Neo-epitopes in Cancer
      • James Wells, Ph.D. - Professor and Chair, Pharmaceutical Chemistry, UCSF
      10:50am - 11:35am45 mins
      Keynote Presentations
      Applications of Machine Learning and Informatics in Antibody and Protein Research
      • Charlotte Deane, PhD - Professor of Structural Bioinformatics, University of Oxford
      11:35am - 12:15pm40 mins
      Keynote Presentations
      Jim Huston Science Talent Award Winner Presentation: Broadly Neutralizing Antibodies to Combat Antigenically Diverse Viruses
      • Laura Walker, Ph.D - Senior Director of Antibody Sciences, Adimab, LLC.
      • Sally Ward, PhD - Professor and Director, University of Southampton
      12:15pm - 1:15pm60 mins
      Scientific Luncheon Briefing 1
      Ablexis / AlivaMab Discovery Services Luncheon
      • Larry Green, PhD - CEO, Ablexis & AlivaMab Discovery Services
      • John "Lippy" Lippincott, PhD - Vice President of Research, AlivaMab Discovery Services
      • Jonah Rainey, PhD - VP of Antibody Engineering and Protein Science, AlivaMab Discovery Services
      12:15pm - 1:15pm60 mins
      Scientific Luncheon Briefing 2
      In Vivo Antibody Discovery with Alloy Therapeutics Mouse Platforms
      • Beau Carson, PhD - Director of External Innovation and Discovery, Alloy Therapeutics
      12:15pm - 1:15pm60 mins
      Scientific Luncheon Briefing 3
      Discovery and Characterization of Nanobodies Directed Against SARS-COV2 Nucleocapsid For Use in Diagnostic Assays
      • Josie Corby - Principal Scientist, Abbott Diagnostics
      • Kathrin Zuberbühler, PhD - Associate Director Antibody Engineering, Large Molecule Discovery at Charles River Laboratories, Antibody Engineering
      12:15pm - 1:15pm60 mins
      Scientific Luncheon Briefing 4
      Discovery, Expression, and Characterization of Neutralizing Picobodies against SARS-CoV2
      • Vaughn Smider, M.D., Ph.D. - President, Applied Biomedical Science Institute
      12:15pm - 1:15pm60 mins
      Scientific Luncheon Briefing 5
      Writing the Future of Biologics Using the Twist Biopharma Library of Libraries
      • Aaron Sato, PhD - Chief Scientific Officer, Twist Bioscience
      1:15pm - 1:45pm30 mins
      Scientific Briefing 1
      Lessons Learned from 2+ Years of Discovering Functional Antibodies on the Beacon
      • Garren Hilow - CHIEF BUSINESS OFFICER, Abveris
      1:15pm - 1:45pm30 mins
      Scientific Briefing 3
      The Leap-In Transposase Platform: Past, Present and Future
      • Oren Beske, Ph.D. - Amalgamator of Business and Biology, ATUM
      1:15pm - 1:45pm30 mins
      Scientific Briefing 4
      MerTK Agonism and Antagonism: Patterns Revealed by Domain Binding Studies Using High Throughput Parallel SPR Analysis on the Carterra LSA
      • Marina Roell - Principal Scientist, Antibody Discovery and Protein Engineering, Alector
      1:15pm - 1:45pm30 mins
      Scientific Briefing 5
      Strategies for High Affinity Screening in Therapeutic Antibody Discovery
      • Palaniswami Rathanaswami, PhD - Senior Scientist, Biologics Discovery, Amgen, Inc.
      1:45pm - 2:15pm30 mins
      Scientific Briefing 1
      Integrating Technologies to Tackle Transmembrane Targets
      • Roza Bidshahri, PhD - Senior Research Scientist & BD Liaison, AbCellera
      1:45pm - 2:15pm30 mins
      Scientific Briefing 2
      Celltheon SMART Platform for DEPs: Scale-up in 200L Allegro STR
      • Divya Goel - VP of Business Development, Celltheon
      1:45pm - 2:15pm30 mins
      Scientific Briefing 4
      Fusion Antibodies
        1:45pm - 2:15pm30 mins
        Scientific Briefing 5
        An Integrated Approach to Managing Immunogenicity Risk and Optimum Protein Design
        • Emilee Knowlton, PhD - Senior Immunology Sales Specialist, ProImmune Inc.
        2:25pm - 2:30pm5 mins
        Track 1: Antibody Repertoires and COVID-19
        Chairwoman’s Remarks
        • Jamie Scott, MD, PhD - Professor and Canada Research Chair , Simon Fraser University
        2:25pm - 2:30pm5 mins
        Track 2: Novel Therapeutic Targets and Non-Cancer Indications
        Co-Chairs’ Remarks
        • Paul Parren, PhD - EVP, Head of R&D and Professor, Lava Therapeutics and Leiden University
        • Katherine Harris, PhD - Vice President, Discovery, Amgen
        2:30pm - 3:00pm30 mins
        Track 1: Antibody Repertoires and COVID-19
        B Cell Clonal Networks: Mapping the Immune Response to SARS-CoV-2
        • Nina Luning Prak, M.D., Ph.D. - Professor of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School
        2:30pm - 3:00pm30 mins
        Track 2: Novel Therapeutic Targets and Non-Cancer Indications
        A Clinical Stage ROR1xCD3 Bispecific Antibody with Potential for Broad Cancer Specificity
        • Kerry Chester, PhD - Professor of Molecular Medicine, UCL Cancer Institute
        3:00pm - 3:30pm30 mins
        Track 1: Antibody Repertoires and COVID-19
        Autoantibodies in COVID-19 Infections and Vaccinations
        • Paul Utz, M.D. - Professor of Medicine - Immunology & Rheumatology, Stanford University School of Medicine
        3:00pm - 3:30pm30 mins
        Track 2: Novel Therapeutic Targets and Non-Cancer Indications
        Targeting Two Receptors Can Significantly Increase Cell Specificity
        • Jonathan Davis, Ph.D. - Vice President of Innovation and Strategy, Invenra, Inc.
        3:30pm - 4:00pm30 mins
        Track 1: Antibody Repertoires and COVID-19
        Convergent Antibody Responses to the SARS-CoV-2 Spike Protein in Convalescent and Vaccinated Individuals
        • Elaine Chen - Graduate Student, Vanderbilt University School of Medicine
        3:30pm - 4:00pm30 mins
        Track 2: Novel Therapeutic Targets and Non-Cancer Indications
        Combination Immunotherapy with CAR T cells and Bispecific Antibodies
        • Bryan Choi, M.D., Ph.D. - Clinical Fellow in Neurosurgery, Massachusetts General Hospital
        4:00pm - 4:45pm45 mins
        Networking Refreshment Break and Opening of Exhibit and Poster Hall
          4:45pm - 5:15pm30 mins
          Track 1: Antibody Repertoires and COVID-19
          The T Cell Response to SARS-COV-2 Vaccines in a World of Variants
          • Harlan Robins, Ph.D. - Chief Scientific Officer and Co-Founder, Adaptive Biotechnologies
          4:45pm - 5:15pm30 mins
          Track 2: Novel Therapeutic Targets and Non-Cancer Indications
          Mitigating Cytokine Release with Novel Low Affinity Anti-CD3 based T-Cell Engagers
          • Udaya Rangaswamy, Ph.D. - Senior Scientist, Amgen
          5:15pm - 5:45pm30 mins
          Track 1: Antibody Repertoires and COVID-19
          Sharing of AIRR-seq Data through the AIRR Data Commons: Standardization, Data Repositories and Data Mining
          • Felix Breden, Ph.D. - Professor, Simon Fraser University
          5:15pm - 5:45pm30 mins
          Track 2: Novel Therapeutic Targets and Non-Cancer Indications
          Novel DARPin® Approaches for the Development of T-cell Engagers with Improved Safety and Efficacy
          • Christian Reichen, Ph.D. - Associate Director Oncology Research, Molecular Partners AG
          5:45pm - 6:15pm30 mins
          Track 1: Antibody Repertoires and COVID-19
          Epitope Profiling of Coronavirus-binding Antibodies Using Computational Structural Modelling
          • Sarah Robinson - Ph.D. Student in Protein Informatics, University of Oxford
          5:45pm - 6:15pm30 mins
          Track 2: Novel Therapeutic Targets and Non-Cancer Indications
          The Conditionally Activated COBRA Demonstrates an Improved Therapeutic Window over Conventional T-cell Engagers in the Solid Tumor Space
          • Danielle Dettling - Senior Director, Pre-Clinical Pharmacology, Maverick Therapeutics
          6:15pm - 7:45pm90 mins
          Opening Night Networking Reception, Exhibits and Poster Viewing
            PRE-CONFERENCE WORKSHOPS (pm only) and TRAINING COURSE (full day)
            NextMAIN CONFERENCE DEC.14
            Filter
            Streams
            Formats
            Choose Day